Triptans (片頭痛/Migraine)：医薬品市場予測及び分析（～2023）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17
3.2.1 Premonitory Phase 18
3.2.2 Aura Phase 18
3.2.3 Headache Phase 19
3.2.4 Postdrome Phase 19
4 Disease Management 20
4.1 Treatment Overview 20
4.1.1 Acute Migraine Treatment 23
4.1.2 Preventive Migraine Treatment 24
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Triptans 27
6.1 Overview 27
6.2 SWOT Analysis 29
6.3 Imitrex (sumatriptan) 29
6.3.1 Overview 29
6.3.2 Efficacy 30
6.3.3 Safety 31
6.3.4 Forecast 31
6.4 Zomig (zolmitriptan) 32
6.4.1 Overview 32
6.4.2 Efficacy 33
6.4.3 Safety 34
6.4.4 Forecast 34
6.5 Amerge (naratriptan) 35
6.5.1 Overview 35
6.5.2 Efficacy 35
6.5.3 Safety 36
6.5.4 Forecast 36
6.6 Maxalt (rizatriptan) 37
6.6.1 Overview 37
6.6.2 Efficacy 37
6.6.3 Safety 39
6.6.4 Forecast 39
6.7 Axert (almotriptan) 40
6.7.1 Overview 40
6.7.2 Efficacy 41
6.7.3 Safety 41
6.7.4 Forecast 41
6.8 Frova (frovatriptan) 42
6.8.1 Overview 42
6.8.2 Efficacy 43
6.8.3 Safety 43
6.8.4 Forecast 44
6.9 Relpax (eletriptan) 44
6.9.1 Overview 44
6.9.2 Efficacy 45
6.9.3 Safety 45
6.9.4 Forecast 46
7 Appendix 47
7.1 Bibliography 47
7.2 Abbreviations 51
7.3 Methodology 52
7.4 Forecasting Methodology 52
7.4.1 Diagnosed Migraine Patients 52
7.4.2 Percent Drug-treated Patients 52
7.4.3 General Pricing Assumptions 53
7.4.4 Individual Drug Assumptions 54
7.4.5 Generic Erosion 57
7.5 Physicians and Specialists Included in this Study 58
7.6 Survey of Prescribing Physicians 59
7.7 About the Authors 60
7.7.1 Author 60
7.7.2 Reviewer 60
7.7.3 Global Head of Healthcare 61
7.8 About GlobalData 62
7.9 Disclaimer 62